Metamark Receives Laboratory License in Preparation to Launch ProMark™
News Mar 01, 2014
Metamark Genetics, Inc. has announced that its Cambridge, Mass. laboratory has been licensed for the highest level of clinical testing in the use of ProMark™, the company's prognostic assay to guide the medical management of patients with prostate cancer.
The licensure by the State of Massachusetts for "high-complexity testing" establishes the CLIA-certified laboratory as the national site for processing prostate-tissue samples upon the commercial introduction of ProMark™ planned for early 2014.
The licensure follows the completion last year of a clinical-validation study of ProMark™ that met its primary endpoint in differentiating between aggressive and indolent disease. Altogether, Metamark has completed four clinical studies of ProMark™ comprising 1,275 patients.
Shawn Marcell, President and Chief Executive Officer of Metamark, commented: "With the licensure of our Cambridge laboratory we have taken another step toward launching ProMark™ so physicians and their patients can use this novel prognostic to address one of the most agonizing questions in men's healthcare-whether a newly diagnosed prostate cancer will spread or whether it will harmlessly remain within the prostate.
"As we prepare to commercialize ProMark™, we are also designing additional clinical studies to further delineate the potential of this new tool to guide the decision whether to treat prostate cancer aggressively or to choose the conservative option of active surveillance.
Marcell continued, "We believe the unique format of ProMark™, which enables objective measurement of protein biomarkers in intact prostate tissue, can improve the management of prostate cancer much as other molecular tools have improved the treatment of breast and ovarian cancer."
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.
Researchers Zoom in on DNA Code Being Read in CellsNews
Scientists have unveiled incredible images of how the DNA code is read and interpreted – revealing new detail about one of the fundamental processes of life. The mechanism for reading DNA and decoding it to build proteins for their needs is common to all animals and plants, and is often hijacked by cancer. The discovery of exactly how the molecular mechanism works, could open up new approaches to cancer treatment.READ MORE